. 2004 Oct;61(19-20):2428–2430. doi:10.1007/s00018-004-4257-y
The SARS-CoV S glycoprotein
X Xiao1,D S Dimitrov1,✉
X Xiao
1Protein Interactions Group, LECB, CCR, NCI-Frederick, NIH, Building 469, Room 105, Frederick, Maryland 21702-1201 USA
Find articles byX Xiao
D S Dimitrov
1Protein Interactions Group, LECB, CCR, NCI-Frederick, NIH, Building 469, Room 105, Frederick, Maryland 21702-1201 USA
Find articles byD S Dimitrov
1Protein Interactions Group, LECB, CCR, NCI-Frederick, NIH, Building 469, Room 105, Frederick, Maryland 21702-1201 USA
✉
Corresponding author.
© Birkhäuser Verlag, Basel 2004
PMCID: PMC7079772 PMID:15526150
Abstract.
The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. Recent rapid advances in our knowledge of the structure and function of this protein have lead to the development of a number of candidate vaccine immunogens and SARS-CoV entry inhibitors.
Key words. SARS, S glycoprotein, S protein, virus, fusion, entry, ACE2
Footnotes
Received 8 July 2004; accepted 12 July 2004